The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Swedish National Diabetes Registry data show a correlation of improved glycemic control in people with type 1 diabetes (T1D) with increased use of diabetes technologies over the past 25 years. However, novel technologies are often associated with a high initial outlay. The aim of the present study was to evaluate the long-term cost-effectiveness of the advanced hybrid closed-loop (AHCL) MiniMed 780G system versus intermittently scanned continuous glucose monitoring (isCGM) plus self-injection of multiple daily insulin (MDI) or continuous subcutaneous insulin infusion (CSII) in people with T1D in Sweden. METHODS: Outcomes were projected over patients' lifetimes using the IQVIA CORE Diabetes Model (v9.0). Clinical data, including changes in glycated hemoglobin (HbA1c) and hypoglycemia rates, were sourced from observational studies and a randomized crossover trial. Modeled patients were assumed to receive the treatments for their lifetimes, with HbA1c kept constant following the application of treatment effects. Costs were accounted from a societal perspective and expressed in Swedish krona (SEK). Utilities and days off work estimates were taken from published sources. RESULTS: The MiniMed 780G system was associated with an improvement in life expectancy of 0.16 years and an improvement in quality-adjusted life expectancy of 1.95 quality-adjusted life years (QALYs) versus isCGM plus MDI or CSII. These clinical benefits were due to a reduced incidence and a delayed time to onset of diabetes-related complications. Combined costs were estimated to be SEK 727,408 (EUR 72,741) higher with MiniMed 780G, with treatment costs partially offset by direct cost savings from the avoidance of diabetes-related complications and indirect cost savings from the avoidance of lost workplace productivity. The MiniMed 780G system was associated with an incremental cost-effectiveness ratio of SEK 373,700 per QALY gained. CONCLUSIONS: Based on a willingness-to-pay threshold of SEK 500,000 per QALY gained, the MiniMed 780G system was projected to be cost-effective versus isCGM plus MDI or CSII for the treatment of T1D in Sweden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185
Wild, D., von Maltzahn, R., Brohan, E., Christensen, T., Clauson, P., & Gonder-Frederick, L. (2007) · Patient Education and Counseling · doi:10.1016/j.pec.2007.05.003 · Cited by 545
Bergenstal, R. M., Nimri, R., Beck, R. W., Criego, A., Laffel, L., Schatz, D., Battelino, T., Danne, T., Weinzimer, S. A., Sibayan, J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32514-9 · Cited by 344
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group (2015) · Diabetes · doi:10.2337/db14-0930 · Cited by 333
Collyns, O. J., Meier, R. A., Betts, Z. L., Chan, D. S. H., Frampton, C., Frewen, C. M., Hewapathirana, N. M., Jones, S. D., Roy, A., Grosman, B., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2250 · Cited by 276 · cited 5×
“5% in the MiniMed 780G arm (based on the findings of the US Pivotal trial) [17].”
MethodResultInfluentialCharleer, S., De Block, C., Van Huffel, L., Broos, B., Fieuws, S., Nobels, F., Mathieu, C., & Gillard, P. (2020) · Diabetes Care · doi:10.2337/dc19-1610 · Cited by 261
Forlenza, G. P., Li, Z., Buckingham, B. A., Pinsker, J. E., Cengiz, E., Wadwa, R. P., Ekhlaspour, L., Church, M. M., Weinzimer, S. A., Jost, E., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0771 · Cited by 246 · cited 1×
“Combinations of CGM and CSII in sensor-augmented pumps (SAPs) can also embed predictive lowglucose management (PLGM) functions that, due to the communication between the two devices, allows partially automated insulin delivery based on blood glucose levels, improving glycemic control and reducing the risk of hypoglyce…”
BackgroundLind, M., Pivodic, A., Svensson, A.-M., Ólafsdóttir, A. F., Wedel, H., & Ludvigsson, J. (2019) · BMJ · doi:10.1136/bmj.l4894 · Cited by 175
Fenwick, E. K., Xie, J., Ratcliffe, J., Pesudovs, K., Finger, R. P., Wong, T. Y., & Lamoureux, E. L. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.11-8992 · Cited by 101
Cited by
Choudhary, P., Kolassa, R., Keuthage, W., Kroeger, J., Thivolet, C., Evans, M., Ré, R., de Portu, S., Vorrink, L., Shin, J., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00212-1 · Cited by 204
Self-citationJendle, J., & Reznik, Y. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15087 · Cited by 26
Self-citationMathieu, C., Ahmed, W., Gillard, P., Cohen, O., Vigersky, R., de Portu, S., & Ozdemir Saltik, A. Z. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0438 · Cited by 16
Self-citation
Metadata
- Authors
- Jendle, J., Buompensiere, M. I., Holm, A. L., de Portu, S., Malkin, S. J. P., & Cohen, O.
- Venue
- Diabetes Therapy
- Published
- 2021-10-01
- Volume
- 12
- Issue
- 11
- Pages
- 2977-2991
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- OpenAlex
- W3202977690
- Cited by
- 40
- References
- 9
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden. https://app.cochat.ai/papers/10.1007/s13300-021-01157-0
- The paper
- Jendle, J., Buompensiere, M. I., Holm, A. L., de Portu, S., Malkin, S. J. P., & Cohen, O. (2021). The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden. Diabetes Therapy. https://doi.org/10.1007/s13300-021-01157-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.